2023-03-03
2022 was a year of many successes, with several important milestones achieved. CEO Kristina Torfgård comments the year-end report and the progress for 2022 in the BioStock article. …
Read more
2023-02-10
Read why Sebastian joined the company and what his mission will be at Alzinova AB. Read more
2023-01-27
Sebastian will be responsible for the continued business development that runs parallel to the further development of the Company's… Read more
2023-01-18
Kristina Torfgård, CEO, commenting on recent exciting events for both the company and the industry in general. Read more
2023-01-13
Alzinova's CEO Kristina Torfgård was interviewed about the accelerated approval of lecanemab… Read more
2023-01-05
Anders tells more about the new exciting data for ALZ-201 antibody and the findings and conclusions as well as… Read more
2023-01-04
In the prestigious journal Alzheimer's Research & Therapy, Alzinova presents preclinical results demonstrating that the ALZ-201 antibody has specificity… Read more
2022-12-23
Alzinova's CEO Kristina Torfgård was interviewed about the latest news on the Companies vaccine candidate ALZ-101 against Alzheimer's disease. Read more
2022-12-19
Watch our CEO Kristina Torfgård, present Alzinova (in Swedish). Read more
2022-12-02
Alzinova's CSO Anders Sandberg was interviewed about the Companies monoclonal antibody ALZ-201 that is presented in a poster presentation… Read more
2022-11-30
This week, Alzinova presents data for the Company's preclinical antibody candidate ALZ-201 at the conference in a poster presentation… Read more
2022-11-15
Alzinova AB presents its company and projects to investors and international pharmaceutical companies at several events during the fall. Next… Read more
2022-11-14
“We see that this outcome proves and further strengthens the company's research because we already have indications that specificity… Read more
2022-11-11
Alzinova is featured in this Sifted article where CEO Kristina Torfgård comments the importance of research hubs such as the AZ BioVentureHub. Read more
2022-11-04
2022-10-24
Watch the new interview (in Swedish). Read more
2022-10-14
2022-10-13
Mangold sees the case for Alzinova's ALZ-101 candidate strengthened considerably. In an updated analysis, Mangold sees advantages in Alzinova's… Read more
2022-09-30
We are happy to see progress in the field of Alzheimer research with new results in the industry that… Read more
2022-09-14
Alzinova AB is a proud sponsor of Alzheimerfonden and will participate in their seminar the 21st of September 2022. CEO Kristina Torfgård together with… Read more
2022-09-07
The company announced that the Data Safety Monitoring Board (DSMB) completed an additional planned safety assessment of the ongoing… Read more
2022-09-01
September marks the start of World Alzheimer's awareness month. It's important to highlight and bring awareness to this devastating… Read more
2022-07-12
Redeye discussed the outlook forward and recent rights issue, among other things. "We believe that Alzinova offers a rare… Read more
2022-06-21
Redeye AB has revisited the Alzinova equity story following continued pipeline progress and the recent rights issue: "We continue to see… Read more
2022-06-13
Alzinova is collaborating with researchers at Sahlgrenska University Hospital in Gothenburg regarding biomarker research for neurodegenerative changes in Alzheimer's disease. Read more
2022-06-08
On June 8, our CEO, Kristina Torfgård, presented at BioStock Life Science Spring Summit. Read more
2022-06-07
Kristina Torfgård, CEO, and Anders Sandberg, CSO, were interviewed by the podcast "Fill or Kill". Read more
2022-06-03
Kristina visited Biostock's studio to talk about how Alzinova differs from other companies developing treatments for Alzheimer's disease. She… Read more
2022-06-02
Alzinova recently participated in the Redeye Growth Day 2 June 2022. Check out the Q&A session with our CEO,… Read more
2022-06-01
Alzinova has taken the next important step to take ALZ-201 towards clinical studies by initiating the development of a… Read more
2022-05-30
”Attempts to develop effective drugs for Alzheimer's disease have been going on for several decades, but so far no… Read more
2022-05-20
Kristina Torfgård, our CEO, presented Alzinova at Aktieportföljen Live on May 11. Read more
2022-05-11
We are proud to sponsor the Alzheimer race, which takes place this weekend, May 13-15. Read more
2022-05-04
"Alzinova lägger grunden för nästa utvecklingssteg"… Read more
On May 3, Kristina Torfgård, CEO, and Anders Sandberg, CSO participated in a panel discussion on Alzheimer's disease. Read more
2022-04-14
In the article (in Swedish) linked below, our CEO, Kristina Torfgård, comments on the recent decision by the the… Read more
2022-04-10
Anders Sandberg, Chief Scientific Officer, about our improved manufacturing process for our oligomer-specific vaccine, ALZ-101. Read more
2022-03-16
We are proud to be part of the BioVentureHub on the AstraZeneca Gothenburg site in the wider GoCo Health… Read more
2022-02-04
Kristina Torfgård, CEO, Anders Sandberg, CSO, and Håkan Skogström, CFO, were interviewed by our Communications Specialist, Jamie Smith, at… Read more
2022-01-28
Check out this article (in Swedish) by BioStock - Connecting Innovation and Capital featuring an interview with our Chief… Read more
2022-01-27
On January 26, our CEO, Kristina Torfgård, presented Alzinova at Mangold Insight Life Science Investent day. Read more
2022-01-17
We're proud to be partnering with Alzheimerfonden. In line with our vision to enable patients to live an independent… Read more
2022-01-14
Our CEO, Kristina Torfgård presented Alzionva at RedEye Investor Forum Online on January 13. Read more
2022-01-12
Like us, you probably know someone who has, or has had, Alzheimer’s disease. It is a progressively debilitating disease… Read more
2022-01-05
The European Medicines Agency (EMA) recently recommended the refusal of the marketing authorisation for Aduhelm, a medicine intended for the treatment… Read more
2022-01-03
2021-12-20
“Alzinova vill knäcka Alzheimer-gåtan”… Read more
2021-11-29
On November 24, our CEO Kristina Torfgård, presented Alzinova at Aktieportföljen. Read more
2021-11-19
"Yesterday, Biogen received a negative trend vote on the aducanumab (Aduhelm) Marketing Authorization application, following an oral explanation held… Read more
2021-11-15
"Trial Testing ALZ-101 Alzheimer’s Vaccine Recruits First Patient - The first patient has been recruited, in Finland, for Alzinova… Read more
2021-11-03
Redeye AB has revisited the Alzinova equity story with the initiation of clinical trials with ALZ-101, our vaccine candidate… Read more
